What restraint-free care actually looks like

Removing restraints without putting anything in their place is not restraint-free care. The 49 items that have to come first.

“We do not use restraints” is a claim about an outcome. Restraint-free care is a claim about 49 items of work that produce it.

The two kinds, and which one hides

Physical restraint is visible: anything a resident cannot remove or leave, including some bed rails and some chairs. Chemical restraint is not visible, because it appears in the chart as a medication — a sedative or antipsychotic given to manage behavior rather than to treat a diagnosed condition.

The second is the one a walkthrough misses and a medication review finds.

Behavior is communication

A resident with dementia who has lost the other channels will tell you something is wrong by behaving. The CareGuard review names the usual causes explicitly, and the list is short and physical: pain, discomfort, boredom, confusion, and underlying conditions including urinary tract infection, dehydration, infection and dementia progression.

One of those causes is worth handling carefully, because getting it wrong produces its own harm. New confusion is a reason to assess. It is not, on its own, a reason to culture urine and start an antibiotic — infectious-disease guidance recommends against exactly that, and a quarter to half of long-term care residents carry bacteria in the urine without infection. The evidence on that.

What has to happen before a restraint is even discussed

Assessment — physical, mental and emotional; root cause of the behavior; history reviewed for underlying conditions; input from family on past triggers; regular reassessment.
Eight non-pharmacological interventions — routine, safe physical activity, meaningful engagement, a calm environment, redirection, frequent hydration and bathroom breaks, comfort items, seating that supports safe mobility.
De-escalation — staff trained in verbal de-escalation, calm communication, time to process, simple language and non-verbal cues, offering choices, involving familiar people.
Pain and comfort — regular pain assessment especially for non-verbal residents, and non-drug relief.
Environmental modification — hazards removed, lighting and temperature right, familiar objects, free movement within secure areas.
Passive monitoring — bed or chair alarms used as a fall-prevention measure without restraint, increased observation, regular check-ins, early intervention.
Care planning — an individualized plan built with providers and family, reviewed in team meetings, and known to all staff.
Medication review — regular review to avoid oversedation, consideration of reducing or deprescribing unnecessary psychotropics, side-effect monitoring.
Trigger work — identifying and minimizing environmental and emotional triggers, quiet retreat space, consistent familiar staff.
Family involvement — participation in behavior management, education on the harms of restraints, open communication about strategy.
Legal and ethical compliance — staff trained on state and federal rules against unnecessary restraints, facility policy followed, restraints used only as a last resort in emergencies with documentation and oversight, and residents and families informed of their rights.

All 49 items, in full.

The honest version of the position

The last item is the one that keeps this from being a slogan. The position is not that a restraint is never used under any circumstance. It is that using one is an emergency event, documented as such, with oversight — not a standing arrangement that quietly becomes how a resident lives.

CareGuard’s position on restraints · DWARAA.

The evidence on antipsychotics in dementia

The mortality signal, and where the label came from

A 2005 meta-analysis of 15 randomized placebo-controlled trials (3,353 patients on drug, 1,757 on placebo) found death in 3.5% of drug-treated patients versus 2.3% on placebo, odds ratio 1.54 (95% CI 1.06 to 2.23). The FDA’s own analysis of 17 placebo-controlled trials, stated in the current approved labeling, puts it this way: “a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.” The boxed warning followed for atypical antipsychotics in 2005 and was extended to conventional antipsychotics in 2008.

The label also records cerebrovascular adverse reactions, including fatalities, at a significantly higher incidence than placebo in elderly patients with dementia-related psychosis.

And the efficacy side

CATIE-AD randomized 421 outpatients across 42 sites for up to 36 weeks and found no significant difference between treatments in time to discontinuation for any reason. Discontinuation for intolerability ran at 24% (olanzapine), 16% (quetiapine), 18% (risperidone) and 5% (placebo). Its conclusion is one sentence: “Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs.”

Withdrawal

The DART-AD discontinuation trial in 165 UK care-facility residents found 12-month survival of 70% (95% CI 58 to 80) in those continuing antipsychotics versus 77% (64 to 85) on placebo, hazard ratio 0.58 (0.35 to 0.95). At 24 months the gap was 46% versus 71%; at 36 months, 30% versus 59%.

A Cochrane review of nine randomized trials (606 participants, seven in nursing homes) concluded that “many older people with Alzheimer’s dementia and NPS can be withdrawn from chronic antipsychotic medication without detrimental effects on their behaviour” — with an important exception: two studies of people whose agitation or psychosis had previously responded well to antipsychotic treatment found an increased risk of relapse after discontinuation. Withdrawal is not uniformly safe and is not a policy to apply across a building without individual assessment.

What happened when a country tried it at scale

Antipsychotic use in US nursing homes reached 23.9% of residents by 2011. Following the National Partnership to Improve Dementia Care launched in 2012, use had declined 40.1% to 14.3% by the second quarter of 2019. Notably, sedative-hypnotic use did not rise to compensate — it declined in tandem. The evaluation’s own conclusion about what made it work: “Adequate staffing, particularly of registered nurses, is key.”

The substitution risk a safety review should look for

A repeated cross-sectional study of more than 70,000 Ontario nursing home residents per quarter from 2010 to 2019 found antipsychotic use falling 0.70% per year and benzodiazepine use 1.17% per year — while antidepressant use rose 0.89% per year and anticonvulsant use 1.06% per year. Over the same window the coding of delusions rose from 3.5% to 10.2%, while coded schizophrenia stayed flat.

That last figure is the one an owner should care about. A falling antipsychotic rate can mean better care, or it can mean a different drug class and a different diagnosis code. A review that only reads the headline metric cannot tell the two apart.

References

Schneider LS, Dagerman KS, Insel P 2005. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15):1934-43. [meta-analysis, 15 trials] · PMID 16234500 · doi:10.1001/jama.294.15.1934
US Food and Drug Administration 2026. RISPERDAL (risperidone) prescribing information, boxed warning and section 5.1. FDA-approved label, effective 2026-05-28. [FDA-approved drug label] · Source
Schneider LS, et al. 2006. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease (CATIE-AD). New England Journal of Medicine 355(15):1525-38. [randomized controlled trial, 421 outpatients] · PMID 17035647 · doi:10.1056/NEJMoa061240
Ballard C, et al. 2009. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology 8(2):151-7. [randomized discontinuation trial, 165 care-facility residents] · PMID 19138567 · doi:10.1016/S1474-4422(08)70295-3
Declercq T, et al. 2013. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database of Systematic Reviews (3):CD007726. [Cochrane review, 9 RCTs] · PMID 23543555 · doi:10.1002/14651858.CD007726.pub2
Jeste DV, et al. 2008. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33(5):957-70. [expert white paper] · PMID 17637610 · doi:10.1038/sj.npp.1301492
Crystal S, et al. 2020. National Partnership to Improve Dementia Care in Nursing Homes campaign: state and facility strategies, impact, and antipsychotic reduction outcomes. Innovation in Aging 4(3):igaa018. [national mixed-methods evaluation] · PMID 32699827 · doi:10.1093/geroni/igaa018
Harris DA, et al. 2022. Potential unintended consequences of antipsychotic reduction in Ontario nursing homes. Journal of the American Medical Directors Association 23(6):1066-1072.e7. [repeated cross-sectional, 2010-2019] · PMID 35143749 · doi:10.1016/j.jamda.2021.12.043